Olivier Loeillot - Sep 3, 2024 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Chief Executive Officer, Director
Signature
/s/ Kenneth O'Brien (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Sep 3, 2024
Transactions value $
$0
Form type
4
Date filed
9/4/2024, 08:41 PM
Previous filing
Feb 29, 2024
Next filing
Nov 21, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +17.6K +111.69% $0.00 33.4K Sep 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +16.3K $0.00 16.3K Sep 3, 2024 Common Stock 16.3K $141.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Loeillot was awarded 17,631 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 One third of the stock options will vest and become exercisable annually on September 3, 2025, September 3, 2026, and September 3, 2027.